Fifteen companies have agreed to share their libraries of compounds
that already have some degree of safety and activity data.
Successful hits would move rapidly into in vivo trials in as little
as two months, Novartis said in a statement on Thursday.
(Reporting by Silke Koltrowitz, editing by John Revill)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |